GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » Price-to-Tangible-Book
Switch to:

Biohaven (NYSE:BHVN) Price-to-Tangible-Book

: 8.28 (As of Today)
View and export this data going back to 2022. Start your Free Trial

As of today (2023-01-31), Biohaven's share price is $18.58. Biohaven's Tangible Book per Share of Sep. 2022 for the quarter that ended in Sep. 2022 was $2.24. Hence, Biohaven's Price to Tangible Book Ratio of today is 8.28.

The historical rank and industry rank for Biohaven's Price-to-Tangible-Book or its related term are showing as below:

BHVN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.81   Med: 2.81   Max: 8.55
Current: 8.29

During the past 2 years, Biohaven's highest Price to Tangible Book Ratio was 8.55. The lowest was 2.81. And the median was 2.81.

BHVN's Price-to-Tangible-Book is ranked worse than
85.83% of 1327 companies
in the Biotechnology industry
Industry Median: 2.87 vs BHVN: 8.29

A closely related ratio is called PB Ratio. As of today, Biohaven's share price is $18.58. Biohaven's Book Value per Sharefor the quarter that ended in Sep. 2022 was $2.80. Hence, Biohaven's P/B Ratio of today is 6.64.


Biohaven Price-to-Tangible-Book Historical Data

The historical data trend for Biohaven's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Annual Data
Trend Dec20 Dec21
Price-to-Tangible-Book
- -

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22
Price-to-Tangible-Book Premium Member Only - - - - 2.81

Competitive Comparison

For the Biotechnology subindustry, Biohaven's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Biohaven's Price-to-Tangible-Book falls in comparison to its industry or sector. The grey bar indicates the Price-to-Tangible-Book's extreme value range as defined by GuruFocus.



Biohaven Price-to-Tangible-Book Calculation

Biohaven's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2022 )
=18.58/2.244
=8.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Biohaven Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Biohaven's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
Executives
Robert J Hugin director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET UNIT# PH1N NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership